alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › disease-modifying-drug

disease-modifying-drug

2 studies tagged disease-modifying-drug, dated 2019-04-19 to 2024-09-01. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. [Pathogenesis and Treatment of Amyloid-related Imaging Abnormalities Caused by Disease-modifying Drugs in Alzheimer's Disease] 2024-09-01
  2. Promising therapies for the treatment of frontotemporal dementia clinical phenotypes: from symptomatic to disease-modifying drugs 2019-04-19

Studies

2 studies carry this tag.

Date range

2019 to 2024

Top journals

  • Brain and nerve = Shinkei kenkyu no shinpo 1
  • Expert opinion on pharmacotherapy 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. [Pathogenesis and Treatment of Amyloid-related Imaging Abnormalities Caused by Disease-modifying Drugs in Alzheimer's Disease]

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Brain and nerve = Shinkei kenkyu no shinpo 2024-09-01 Treatments

    Amyloid-related imaging abnormalities (ARIA) represent the most frequent adverse effect of lecanemab, a monoclonal antibody drug that targets amyloid beta.

  2. Promising therapies for the treatment of frontotemporal dementia clinical phenotypes: from symptomatic to disease-modifying drugs

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Expert opinion on pharmacotherapy 2019-04-19 Drug development

    Frontotemporal dementia (FTD) is a heterogeneous clinical entity that includes several disorders characterized by different cellular mechanisms.

All topic tags with their study counts